Evidence map›Paper›PMID 38969944›Full record

ArticleBreast cancer research and treatment2024

Sustained delivery of celecoxib from nanoparticles embedded in hydrogel injected into the biopsy cavity to prevent biopsy-induced breast cancer metastasis.

Reese Simmons, Hiroyasu Kameyama, Seiko Kubota, Yunguang Sun, John F Langenheim, Rana Ajeeb, Tristan S Shao, Samantha Ricketts, Anand C Annan, Natalie Stratemeier and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Reese SimmonsStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Hiroyasu KameyamaStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Seiko KubotaStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Yunguang SunDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
John F LangenheimDepartment of Pharmacology, Physiology & Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Rana AjeebStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK, 73019, USA.
Tristan S ShaoStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Samantha RickettsDepartment of Pathology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Anand C AnnanDepartment of Pathology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Natalie StratemeierDepartment of Radiological Sciences, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Sophie J WilliamsDepartment of Pathology, School of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
John R CleggInstitute for Biomedical Engineering, Science, and Technology, University of Oklahoma, Norman, OK, 73019, USA.
Kar-Ming FungStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Inna ChervonevaDivision of Biostatistics, Department of Pharmacology, Physiology & Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Hallgeir RuiDepartment of Pharmacology, Physiology & Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA.
Takemi TanakaStephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA. takemi-tanaka@ouhsc.edu.ORCID http://orcid.org/0000-0001-5231-4528

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ROBERT S. MANNEL · 2018 to 2026
$27.1M
TUMOR RESISTANCE MECHANISMS TO ANTI-VEGF THERAPY IN PROSTATE CANCER (Sukyung Woo)P20GM103639 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI DHANASEKARAN, DANNY N. · 2012 to 2022
$21.3M
NCI NIH HHS P30 CA225520NIGMS NIH HHS P20 GM103639U.S. Department of Defense W81XWH-19-1-0356U.S. Department of Defense W81XWH-19-1-0357U.S. Department of Defense W81XWH-20-1-0554U.S. Department of Defense W81XWH-20-1-0555U.S. Department of Defense W81XWH-21-1-0003
6 · The paper itself

Abstract

purposeWe have previously reported that protracted Cyclooxygenase-2 (COX-2) activity in bone marrow-derived cells (BMDCs) infiltrating into biopsy wounds adjacent to the biopsy cavity of breast tumors in mice promotes M2-shift of macrophages and pro-metastatic changes in cancer cells, effects which were suppressed by oral administration of COX-2 inhibitors. Thus, local control of COX-2 activity in the biopsy wound may mitigate biopsy-induced pro-metastatic changes.

methodsA combinatorial delivery system-thermosensitive biodegradable poly(lactic acid) hydrogel (PLA-gel) incorporating celecoxib-encapsulated poly(lactic-co-glycolic acid) nanoparticles (Cx-NP/PLA-gel)-was injected into the biopsy cavity of Py230 murine breast tumors to achieve local control of COX-2 activity in the wound stroma.

resultsA single intra-biopsy cavity injection of PLA-gel loaded with rhodamine-encapsulated nanoparticles (NPs) showed sustained local delivery of rhodamine preferentially to infiltrating BMDCs with minimal to no rhodamine uptake by the reticuloendothelial organs in mice. Moreover, significant reductions in M2-like macrophage density, cancer cell epithelial-to-mesenchymal transition, and blood vessel density were observed in response to a single intra-biopsy cavity injection of Cx-NP/PLA-gel compared to PLA-gel loaded with NPs containing no payload. Accordingly, intra-biopsy cavity injection of Cx-NP/PLA-gel led to significantly fewer metastatic cells in the lungs than control-treated mice.

conclusionThis study provides evidence for the feasibility of sustained, local delivery of payload preferential to BMDCs in the wound stroma adjacent to the biopsy cavity using a combinatorial delivery system to reduce localized inflammation and effectively mitigate breast cancer cell dissemination.

Indexed as

Breast NeoplasmsCelecoxibHydrogelsNanoparticlesAnimalsBiopsyCell Line, TumorCyclooxygenase 2 InhibitorsDelayed-Action PreparationsDisease Models, AnimalDrug CarriersDrug Delivery SystemsFemaleHumansMacrophagesMiceCelecoxibCyclooxygenase 2 InhibitorsDelayed-Action PreparationsDrug CarriersHydrogelsPolyestersPolylactic Acid-Polyglycolic Acid CopolymerBiopsyBiopsy site markerHydrogelLocal drug deliveryMetastasisNanoparticle

Identifiers

PMID38969944
PMCPMC11452511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.